The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy.

person Joori Kim Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea info_outline Joori Kim, Jeong-Oh Kim, Youn Soo Lee, Jung-Young Shin, Min Young Kim, Mi-Ran Lee, Seoree Kim, Saori Fujita-Sato, Maki Kobayashi, Tomoya Kakegawa, Jin Hyoung Kang

Authors person Joori Kim Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea info_outline Joori Kim, Jeong-Oh Kim, Youn Soo Lee, Jung-Young Shin, Min Young Kim, Mi-Ran Lee, Seoree Kim, Saori Fujita-Sato, Maki Kobayashi, Tomoya Kakegawa, Jin Hyoung Kang Organizations Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Hospital Pathology, Seoul St. Mary’s Hospital, Seoul, South Korea, Division of Medical HematoOncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, South Korea, Daiichi Sankyo Co. Ltd., Tokyo, Japan, Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan, Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Daiichi Sankyo Company, Limited Background: Erb-b2 receptor tyrosine kinase 3 (HER3) is broadly expressed in various types of cancer and is associated with poor prognosis. Recent evidence supports HER3 plays a role in acquired resistance to chemotherapy. The change of HER3 expression by chemotherapy in head and neck squamous cell carcinoma (HNSCC) remains unclear. Methods: We evaluated 95 patients with locally advanced HNSCC who had received induction chemotherapy (ICT) between 2009 and 2019. Immunohistochemical staining for HER3 was performed using formalin-fixed paraffin-embedded surgical specimens and biopsy samples. H-score of membrane staining was evaluated. Results: Median age of patients was 64 years, and 85% were male. Primary locations included oropharynx (54.8%), hypopharynx (21.5%), oral cavity (17.2%), and salivary gland (6.5%). Mean H-score of HER3 in tumor tissues was 77.6 ± 7.9. H-score of HER3 in HPV-positive tumors was higher than HPV-negative tumors (p = 0.019), which was more pronounced in oropharynx and hypopharynx tumors. While, H-score of HER3 in adjacent normal tissues of these tumors did not significantly differ. Compared with the non-smokers, tumor tissues of current or ex-smokers demonstrated higher H-score of HER3 (p = 0.033), independent of tumor location. In contrast, in adjacent normal tissues, no significant differences of H-score of HER3 were observed depending on the smoking status. The H-score higher than 100 was defined as HER3-high group. Among oropharynx and hypopharynx tumors with positive correlation between H-score of HER3 and HPV status (n = 56), HER3-high group was significantly correlated with HPV positivity (p = 0.009) and good response to ICT (p = 0.035). Good clinical response was also strongly related to HPV-positivity (p = 0.001). In addition, there was a tendency for longer overall survival in HER3-high group than low HER3 expression group (93 vs. 70 months, p = 0.053). The paired tumor samples collected at pre- and post-ICT (n = 21) were analyzed. HER3 expressions in adjacent normal tissue were higher at post-ICT compared to pre-ICT (p = 0.003), and these results were more pronounced in the non-smoking group, but no differences were found according to HPV-status. Conclusions: Taken together, our results showed that H-score of HER3 was significantly higher in both HPV-positive and smoking group. Interestingly, high HER3 expression in oropharynx and hypopharynx tumors was associated with HPV positivity and good clinical response to ICT. Additional analysis of tumor immune microenvironment in tumor tissues are underway.